References
  1. Kim MH, Park SH, Cho HJ, Choi JS, Kim JO, Ahn HK, Shin JY. Kim MY, Yang JH. Threshold of nuchal translucency for the detection of chromosomal aberration: comparison of different cutoffs. J Korean Med Sci 2006;21:11-14.
  2. Committee Opinion No.640: Cell-free DNA screening for fetal aneuploidy. Obstet Gynecol 2015;126:e31-37.
  3. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005;192:1005-1021.
  4. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-869.
  5. Bekker MN, Haak MC, Rekoert-Hollander M, Twisk J, Van Vugt JM. Increased nuchal translucency and distended jugular lymphatic sacs on first-trimester ultrasound. Ultrasound Obstet Gynecol 2005;25:239–245.
  6. Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005;29:190–194.
  7. Bilardo CM, Pajkrt E, de Graaf I, Mol BW, Bleker OP. Outcome of fetuses with enlarged nuchaltranslucency and normal karyotype. Ultrasound Obstet Gynecol 1998;11:401–406.
  8. Kim SY, Lee SM, Jun JK, Han YJ, Kim MH, Shim JY, Lee MY, Oh SY, Lee J. Kim SH, Cha DH, Cho GJ, Kwon HS, Kim BJ, Park MH, Cho HY, Ko HS, Ahn J, Ryu HM. Prospective observations study protocol to investigate cost-effectiveness of various prenatal test strategies after the introduction of noninvasive prenatal testing. BMC Pregnancy Childbirth 2018;18:307.
  9. Fetal Medicine Foundation. https://fetalmedicine.org/nuchal-translucency-scan/[12September 2010].
  10. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31:376–383.
  11. Seror V, L’Haridon O, Bussières L, Malan V, Fries N, Vekemans M, Salomon LJ, Ville Y; SAFE 21 Study Group.Women’s Attitudes Toward Invasive and Noninvasive Testing When Facing a High Risk of Fetal Down Syndrome. JAMA Netw Open 2019;2:e191062.
  12. Berger VK, Norton ME, Sparks TN, Flessel M, Baer RJ, Currier RJ. The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cell-free DNA screening. Prenat Diagn 2020;40:185-190.
  13. Nicolaides KH. Nuchal translucency and other first-trimestersonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004;191:45–67.
  14. Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH. Defects and syndromes in chromosomally normal fetuses withincreased nuchal translucency thickness at 10–14 weeks ofgestation. Ultrasound Obstet Gynecol 1998;11:391–400.
  15. Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol 2006;107: 6–10.
  16. ACOG Practice Bulletin No. 163: Screening for fetal aneuploidy. Obstet Gynecol 2016; 127:e123-137.
  17. Shakoor S, Dileep D, Tirmizi S, Rashid S, Amin Y, Munim S.Increased nuchal translucency and adverse pregnancy outcomes. J Matern Fetal Neonatal Med 2017;30:1760-1763.
  18. Lichtenbelt KD, Diemel BD, Koster MP, Manten GT, Siljee J, Schuring-Blom GH, Page-Christiaens GC. Detection of fetal chromosomal anomalies: does nuchal translucency measurement have added value in the era of non-invasive prenatal testing? Prenat Diagn 2015; 35:663–668.
  19. Srebniak MI, de Wit MC, Diderich KE, Govaerts LC, Joosten M, Knapen MF,Bos MJ, Looye-Bruinsma GA, Koningen M, Go AT, Galjaard RJ, Van Opstal D. Enlarged NT (≥3.5 mm) in the first trimester - not all chromosome aberrations can be detected by NIPT. Mol Cytogenet 2016;9:69.
  20. Khalil A, Mahmoodian N, Kulkarni A, Homfray T, Papageorghiou A, Bhide A, Thilaganathan B. Estimation of detection rates of aneuploidy in high-risk pregnancy using an approach based on nuchal translucency and non-invasive prenatal testing: a cohort study. Fetal Diagn Ther 2015;38:254-261.
  21. Bardi F, Bosschieter PFN, Verheij JBGM, Go ATJI, Haak MC, Bekker MN, Sikkel E, Coumans ABC, Pajkrt E, Bilardo CM. Is there still a role for nuchal translucency measurement in the changing paradigm of the changing paradigm of first trimester screening? Prenat Diagn 2020;40:197-205.
  22. Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH. Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities. Fetal Diagn Ther 2014;35:174–84.
  23. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH.Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2017;50:302-314.
  24. Ghi T, Huggon IC, Zosmer N, Nicolaides KH. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 2001;18:610-614.
  25. Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH. Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 2005;26:154-157.
  26. LJ Salomon, A Sotiriadis, CB Wulff, A Odibo, R Akolekar. Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta‐analysis. Ultrasound Obstet Gynecol 2019;54:442-451.